The report is a routine annual update for a pre-revenue clinical-stage biotech. The key catalyst to watch is the progression of IBIO-600 into the multiple ascending dose portion of its Phase 1 trial and the IND filing for IBIO-610. The $88M cash position removes near-term financing risk, but the lack of revenue and widening losses mean the stock will trade on pipeline milestones, not financials. Monitor for any data readouts or regulatory updates on IBIO-600 and IBIO-610.
Price Chart
Executive Summary
iBio reported fiscal year 2026 results with revenue of $0.1M (down from $0.4M) and a net loss of -$33.0M, wider than the -$18.4M loss in FY2025. The company highlighted pipeline progress (IBIO-600 Phase 1, IBIO-610 IND-enabling studies) and a strengthened cash position of $88.0M, extending runway into FY2028. The EPS of -$0.32 was in line with the Street consensus of -$0.06 for the March quarter, but the full-year loss widened significantly due to higher R&D spending and a $5.0M impairment charge, making this a neutral-to-slightly-bearish report for a pre-revenue clinical-stage biotech.
Key Financial Metrics
Key Facts
- Revenue decreased to $0.1M in FY2026 from $0.4M in FY2025.
- Net loss widened to -$33.0M from -$18.4M, driven by higher R&D expenses ($19.6M vs $8.3M) and a $5.0M impairment of indefinite-lived intangible assets.
- Cash and investments totaled $88.0M as of June 30, 2026, up from $8.6M a year ago, extending cash runway into FY2028.
- IBIO-600 Phase 1 trial dosed 31 of 32 planned participants in single ascending dose portion with no safety findings precluding dose escalation.
- IBIO-610 advanced into IND-enabling studies with preclinical data showing fat-selective weight loss and prevention of weight regain after GLP-1 discontinuation.
- Closed a $100M public offering (August 2025) and a $26M private placement (January 2026).
- Entered into an Open Market Sale Agreement with Jefferies for up to $100M of common stock.
- Appointed Molly Carr, M.D. as Chief Medical Officer and Elizabeth Stoner, M.D. to the Board.
Financial Impact
Net loss of -$33.0M on $0.1M revenue; cash burn of ~$35M in operating expenses; $88M cash runway into FY2028.
Risk Factors
- No approved products or recurring revenue; future value depends entirely on clinical trial success.
- High cash burn rate ($35M in operating expenses) could require additional financing before FY2028 if pipeline milestones are delayed.
- Dilution risk from the $100M ATM facility with Jefferies and outstanding warrants from the August 2025 offering.
- Competition in obesity/cardiometabolic space from established GLP-1 therapies and other biotechs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352622 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8210 | awaiting T+5 | — | $0.7415 (−9.68%) |
Oct 14, 2026 12d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7415 (−5.03%) |
Oct 13, 2026 14d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7415 (−5.15%) |
Sep 14, 2026 6w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7415 (−37.69%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7415 (−45.48%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7415 (−45.48%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7415 (−57.63%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7415 (−49.56%) |
May 12, 2026 23w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7415 (+52.16%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7415 (−55.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers